Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 268

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 268
---
35,953 |   |
| Net loss and comprehensive loss for the period |        |             - |     |        |          - |     |   |                          - |     |   | (1,707,358          | ) |   | (1,707,358 | ) |
| Balance as of March 31, 2024                   |        |     8,076,673 |     |        | 18,761,250 |     |   |                    134,538 |     |   | (19,455,745         | ) |   |   (559,957 | ) |
| Conversion of debt                             |        |     1,307,798 |     |        |  5,210,962 |     |   |                          - |     |   | -                   |   |   |  5,210,962 |   |
| Issuance of common shares                      |        |     1,461,250 |     |        |  5,470,000 |     |   |                          - |     |   | -                   |   |   |  5,470,000 |   |
| Stock-based compensation                       |        |             - |     |        |          - |     |   |                    585,442 |     |   | -                   |   |   |    585,442 |   |
| Net loss and comprehensive loss for the period |        |             - |     |        |          - |     |   |                          - |     |   | (3,632,859          | ) |   | (3,632,859 | ) |
| Balance as of June 30, 2024                    |        |    10,846,721 |     | $      | 29,442,212 |     | $ |                    719,980 |     | $ | (23,088,604         | ) | $ |  7,073,588 |   |

<div align='center'>The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

F-28</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>MEDICUS PHARMA LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)</